Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 3:27 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1009–1032 of 4,019 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Part 3 Clear all

Conditions: Obesity & Overweight, Cardiometabolic Health Indicators
Interventions: GLP-1 dose reduction, non-GLP weight loss medication, Maintenance of GLP-1 dose, Resistance exercise regimen, Lifestyle/nutrition counseling; Drug · Behavioral
Lead sponsor: Jing Luo; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Healthy
Interventions: HU6 450 mg Tablet, HU6 150 mg Capsules x 3 (Total dose = 450 mg); Drug
Lead sponsor: Rivus Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Osteoarthritis
Interventions: Not applicable (no therapy is administered as part of this study); Other
Lead sponsor: Biosplice Therapeutics, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 703 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 62
States / cities: Birmingham, Alabama • Oro Valley, Arizona • Phoenix, Arizona + 59 more

Conditions: Healthy Volunteers
Interventions: Testosterone, Goserelin acetate; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 60 Years to 75 Years · Male only
Enrollment: 177 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: HIV
Interventions: ePGT121v1-LS (IV), PGDM1400LS (IV), VRC07-523LS (IV), ePGT121v1-LS (SC), PGDM1400LS (SC), VRC07-523LS (SC); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 83 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 7
States / cities: Birmingham, Alabama • San Francisco, California • Atlanta, Georgia + 4 more

Conditions: HR+ Breast Cancer, Triple Negative Breast Cancer (TNBC), CCNE1 Amplified Advanced Solid Tumors, HR+ HER2- Breast Cancer
Interventions: NKT5097 CDK2/CDK4 dual degrader, Fulvestrant, Letrozole; Drug
Lead sponsor: NiKang Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 361 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 19
States / cities: Duarte, California • La Jolla, California • Denver, Colorado + 16 more

Conditions: Adolescent Idiopathic Scoliosis, Neuromuscular Scoliosis, Perioperative/Postoperative Complications, Iron Deficiencies, Anemia, Spinal Fusion, Postoperative Cognitive Dysfunction
Interventions: Oral ferrous sulfate, Oral placebo tablet; Dietary Supplement
Lead sponsor: Columbia University; Other
Eligibility: 10 Years to 26 Years
Enrollment: 275 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Solid Tumors, Adult
Interventions: HMPL-A251; Drug
Lead sponsor: Hutchmed; Industry
Eligibility: 18 Years and older
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 8
States / cities: Denver, Colorado • Plantation, Florida • Tamarac, Florida + 4 more

Conditions: Head and Neck Cancer, Relapse, Recurrent, Refractory Cancer
Interventions: Cyclophosphamide, Fludarabine, Cell Therapy; Drug · Biological
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Acute Myeloid Leukemia, Leukemia, Myeloid
Interventions: Bioelectrical Impedence Analysis Device, 6 Minute Walk Test, Computed Tomography Scans to Measure Skeletal Muscular Index, Blood Test/Blood Draw, Hand Grip Strength Test; Device · Other · Diagnostic Test
Lead sponsor: University of Chicago; Other
Eligibility: 60 Years and older
Enrollment: 239 participants
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Esophageal Squamous Cell Carcinoma
Interventions: Sintilimab, Cisplatin, Paclitaxel, Fluorouracil, Placebo; Biological · Drug
Lead sponsor: Innovent Biologics (Suzhou) Co. Ltd.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 746 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 7
States / cities: Anaheim, California • Orange, California • Denver, Colorado + 4 more

Conditions: Healthy
Interventions: PF-04308515, Placebo, PF-04308515 Tablet; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed or Refractory Multiple Myeloma (MM)
Interventions: Lymphodepleting chemotherapy: Cyclophosphamide, Lymphodepleting chemotherapy: Bendamustine, Lymphodepleting chemotherapy: Fludarabine, Lisocabtagene Maraleucel, Axicabtagene Ciloleucel, Ciltacabtagene Autoleucel, Low-Dose Total Body Irradiation; Drug · Other · Radiation
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy Volunteers
Interventions: TAK-951 Placebo, TAK-951; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 128 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Glendale, California

Conditions: Type 1 Diabetes
Interventions: Autologous UCB, Omega 3 FA, Vitamin D; Biological · Dietary Supplement
Lead sponsor: University of Florida; Other
Eligibility: 1 Year to 18 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Cancer
Interventions: EC0489, Injection, EC20; Drug
Lead sponsor: Endocyte; Industry
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 6
States / cities: Lafayette, Indiana • Baltimore, Maryland • Bethesda, Maryland + 3 more

Conditions: Healthy Volunteer
Interventions: ABBV-722, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 95 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Cypress, California • Grayslake, Illinois

Conditions: Diabetes, Diabetic Foot Ulcer, Non-healing Wound
Interventions: ExpressGraft-C9T1 Skin Tissue; Biological
Lead sponsor: Stratatech, a Mallinckrodt Company; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 4
States / cities: Phoenix, Arizona • Fresno, California • San Francisco, California + 1 more

Conditions: NASH
Interventions: Pegozafermin, Placebo; Drug · Other
Lead sponsor: 89bio, Inc.; Industry
Eligibility: 21 Years to 75 Years
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 25
States / cities: Madison, Alabama • Chandler, Arizona • Tucson, Arizona + 21 more

Conditions: Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: everolimus, lapatinib ditosylate; Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 6
States / cities: Los Angeles, California • Sacramento, California • Aurora, Colorado + 3 more

Conditions: Multiple Myeloma, Smoldering Multiple Myeloma, Immunoglobulin Light-chain Amyloidosis
Interventions: JNJ-79635322, Daratumumab, Pomalidomide, Lenalidomide; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 276 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 2
States / cities: Denver, Colorado • Atlanta, Georgia

Conditions: Drug Drug Interaction
Interventions: EPX-100, Itraconazole, Phenytoin, Omeprazole, Midazolam, Bupropion; Drug
Lead sponsor: Epygenix; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Parkinson's Disease
Interventions: RO7046015, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 316 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2031
U.S. locations: 26
States / cities: Birmingham, Alabama • Phoenix, Arizona • Fullerton, California + 23 more

Conditions: Healthy Participants
Interventions: Nintedanib, BMS 986278; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 71 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Lenexa, Kansas

Search by objective public record fields.

Comparing Different Medication Regimens to Maintaining Weight Loss Among Adults With Obesity Using GLP-1s

Relative Bioavailability Study of HU6

An Observational Study Evaluating the Safety, Tolerability, and Efficacy of Treatment of SM04690 or Placebo Previously Injected in the Target Knee Joint of Subjects With Moderately to Severely Symptomatic Osteoarthritis

Dose-Response of Gonadal Steroids and Bone Turnover in Older Men

A Study of Safety and Drug Levels of ePGT121v1-LS, PGDM1400LS, and VRC07-523LS in Adult Participants Without HIV-1

A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

Kids With Iron Deficiency and Scoliosis

A Phase Ⅰ/Ⅱa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid Tumors

Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC

Studying Malnutrition And Sarcopenia In Older Adults With Acute Myeloid Leukemia

Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma ( ORIENT-15 )

Multiple Dose Escalation Trial Of PF-04308515 In Healthy Volunteers

Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple Myeloma

A Study of TAK-951 in Healthy Adults

Cord Blood Plus Vitamin D and Omega 3s in T1D

Study of EC0489 for the Treatment of Refractory or Metastatic Tumors

A Study to Assess How the Drug Moves Through the Body, Adverse Events, and Tolerability of Oral ABBV-722 Capsules of Single and Multiple Ascending Doses in Adult Participants and Single Doses in Adult Asian Participants

Multiple Applications of ExpressGraft-C9T1 Skin Tissue as a Treatment for Diabetic Foot Ulcers

A Multiple Ascending Dose Study of Pegozafermin in Participants With Biopsy Confirmed Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) and at High Risk of NASH

S0528 Lapatinib and Everolimus in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma

A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma

Drug-drug Interaction Study of Clemizole (EPX-100) in Healthy Participants

A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease

A Study to Assess the Extent of Drug Interaction Between BMS-986278 and Nintedanib, the Relative Bioavailability of BMS-986278 in Tablet and the Effect That Food Has on BMS-986278 in Tablet Formulations in Healthy Participants